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Abstract
Background: The Hedgehog (Hh) signaling pathway regulates a variety of developmental processes,
including vasculogenesis, and can also induce the expression of pro-angiogenic factors in fibroblasts
postnatally. Misregulation of the Hh pathway has been implicated in a variety of different types of cancer,
including pancreatic and small-cell lung cancer. Recently a putative antagonist of the pathway, Hedgehog-
interacting protein (HIP), was identified as a Hh binding protein that is also a target of Hh signaling. We
sought to clarify possible roles for HIP in angiogenesis and cancer.
Methods: Inhibition of Hh signaling by HIP was assayed by measuring the induction of Ptc-1 mRNA in
TM3 cells treated with conditioned medium containing Sonic hedgehog (Shh). Angiogenesis was assayed
in vitro by EC tube formation on Matrigel. Expression of HIP mRNA was assayed in cells and tissues by
Q-RT-PCR and Western blot. HIP expression in human tumors or mouse xenograft tumors compared to
normal tissues was assayed by Q-RT-PCR or hybridization of RNA probes to a cancer profiling array.
Results:  We show that Hedgehog-interacting protein (HIP) is abundantly expressed in vascular
endothelial cells (EC) but at low or undetectable levels in other cell types. Expression of HIP in mouse
epithelial cells attenuated their response to Shh, demonstrating that HIP can antagonize Hh signaling when
expressed in the responding cell, and supporting the hypothesis that HIP blocks Hh signaling in EC. HIP
expression was significantly reduced in tissues undergoing angiogenesis, including PC3 human prostate
cancer and A549 human lung cancer xenograft tumors, as well as in EC undergoing tube formation on
Matrigel. HIP expression was also decreased in several human tumors of the liver, lung, stomach, colon
and rectum when compared to the corresponding normal tissue.
Conclusion: These results suggest that reduced expression of HIP, a naturally occurring Hh pathway
antagonist, in tumor neo-vasculature may contribute to increased Hh signaling within the tumor and
possibly promote angiogenesis.
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Background
The Hedgehog family of genes encodes secreted signaling
molecules that regulate cell proliferation and cell fate
determination. In mammals, there are three such genes:
Sonic hedgehog (Shh), Indian hedgehog (Ihh), and Desert
hedgehog (Dhh). All three Hedgehog (Hh) proteins func-
tion by binding to the transmembrane receptor, Patched-
1 (Ptc-1), leading to the de-repression of the membrane-
bound inhibitor, Smoothened [1,2]. This results in activa-
tion of the transcription factor Gli-1, which induces
expression of target genes that include Ptc-1 and Gli-1
itself. The increase in expression of Ptc-1 may limit the
range of action of Hh by sequestering it at the surface of
Hh-responsive cells [3].
Hedgehog-interacting protein (HIP) was discovered by
screening a mouse cDNA expression library for proteins
that bound to Shh [4]. HIP binds all three Hh proteins
with an affinity equal to that of Ptc-1, and in mouse
embryos it is expressed in cells adjacent to those express-
ing Shh, positioning it appropriately for in vivo interac-
tions. Ectopic expression of Shh leads to ectopic HIP
expression, indicating that HIP is a transcriptional target
of Hh signaling [4]. Transgenic mice that overexpress HIP
in the endochondral skeleton displayed a phenotype sim-
ilar to that of Ihh knockout mice, consistent with an
inhibitory role for HIP in Hh signaling [4]. Although it
has been shown that overexpression of HIP in cells mak-
ing Shh reduced the amount of Shh secreted into the
media [5], no data has been published specifically dem-
onstrating that expression of HIP in responding cells
inhibits the activation of the Shh signaling pathway.
During gastrulation in the mouse, Ihh is secreted by the
endoderm and is sufficient to activate hematopoiesis and
vasculogenesis [6]. In addition to its role in developmen-
tal processes, Shh was shown to induce angiogenesis in a
murine corneal angiogenesis model, probably through
the induction of the angiogenic factors VEGF, Ang-1, and
Ang-2 [7]. Moreover, inhibition of Shh in the ischemic
hindlimb of mice through the use of a neutralizing anti-
body inhibits endogenous angiogenesis [8]. Hh is also
required for normal angiogenesis in the murine yolk sac,
as Ihh-/- mice can initiate vasculogenesis and hematopoie-
sis but are defective in vascular remodeling to form blood
vessels [9]. In the murine cornea, fibroblasts were identi-
fied as the Shh-responsive cells, while endothelial cells in
the corneal neovessels, as well as human umbilical vein
endothelial cells and microvascular endothelial cells cul-
tured in vitro, were unable to respond to Shh, even though
they express the receptor Ptc-1 [7].
Misregulation of the Hh signaling pathway has been
implicated in several different types of cancer, including
basal cell carcinomas (BCCs), medullablastomas, and gli-
omas (reviewed in [10]. Mutations in Ptc-1, which lead to
constitutive activation of the Hh pathway, are the under-
lying factor in basal cell nevus syndrome, a familial con-
dition characterized by a predisposition to BCC
development [11]. In addition, Gli-1 was originally iden-
tified as a gene overexpressed in a human glioma line
[12]. Recently, it was reported that Hh pathway activity is
upregulated in digestive tract, pancreatic, and small-cell
lung tumors and is required for the growth of these
tumors [13-15].
Here we show that overexpression of HIP in cultured
mouse Leydig cells inhibits the ability of these cells to
respond to exogenous Shh, confirming that HIP can block
Hh signaling when expressed in the same cells as the
receptor Ptc-1. We have also shown that HIP is expressed
predominantly in vascular endothelial cells and is down-
regulated in HUVEC during in vitro angiogenesis. Strik-
ingly, HIP mRNA levels were decreased or even absent in
several types of human tumors, as well as in highly vascu-
larized human tumors grown in nude mice. Taken
together, these results indicate a correlation between ang-
iogenesis and decreased expression of HIP, lending sup-
port to the role of HIP as a naturally occurring regulator of
Hh signaling and neovessel formation in the adult
organism.
Methods
Conditioned media production
Adherent cultures of 293-EBNA cells were transfected with
a Shh-pCDNA3 expression plasmid kindly provided by
Dr. Pao-Tien Chuang (UCSF) using LipofectAMINE 2000
and OptiMem reduced-serum medium (Invitrogen).
Three to five hours after transfection, cells were re-fed with
serum-containing growth medium, and three or four days
later conditioned medium was collected and filtered
through 0.2-µm cellulose acetate filters.
Endothelial cell tube formation assays
For RNA isolation, human aortic endothelial cells (HAEC)
were cultured in 12-well plates with or without Matrigel
(BD Biosciences) for 16 hours, then cells were lysed,
digested with proteinase K, and total RNA was extracted
using the RNeasy Mini Kit (Qiagen). HIP expression was
assayed by real-time quantitative reverse transcriptase
PCR (Q-RT-PCR) and normalized to 18s rRNA (see
below).
Transfection and conditioned medium assays
The mouse testicular epithelial cell line, TM3, was grown
in complete medium (DMEM/F12 with 2.5% FBS, 5%
horse serum, 15 mM Hepes, and 4 mM glutamine) at
37°C and 5% CO2. Cells were transfected in 12-well or
24-well plates at 80–90% confluence using Lipo-
fectAMINE 2000 transfection reagent and OptiMemBMC Cancer 2004, 4:43 http://www.biomedcentral.com/1471-2407/4/43
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reduced-serum medium (Invitrogen). For conditioned
medium (CM) assays, cells were transfected with the plas-
mid MycHIP-pCDNA3 (gift of Dr. Pao-Tien Chuang,
UCSF), which encodes full-length mouse HIP, or empty
vector (mock). Mock or Shh CM was added to cells 36
hours after transfection, then RNA was harvested 36–48
hours later.
Collection of mouse tissues
PC3 human prostate cancer cells were implanted subcuta-
neously into male nude mice (strain nu/nu), and on day
39 the resulting tumors were excised, weighed, placed on
dry ice, then stored at -80°C prior to RNA isolation. A549
lung cancer cells were implanted subcutaneously into
female nude mice and harvested as described above on
day 9. Normal livers or skin from 5- to 6-week-old male or
4- to 5-week-old female nude mice were excised immedi-
ately following cervical dislocation and frozen in liquid
nitrogen, then stored at -80°C.
RNA isolation
RNA was extracted from cultured cells using the RNeasy
kit (Qiagen), including on-column DNase I digestion,
according to the manufacturer's instructions. To extract
RNA from frozen normal mouse tissues and tumors, hard-
frozen tissue samples of 100–300 µg were pulverized over
dry ice, placed in denaturing buffer, and disrupted using a
Mixer Mill (Retsch) or rotor-stator homogenizer (Omni
International). RNA was isolated from the homogenate
either by phenol-chloroform extraction followed by pre-
cipitation with isopropanol and washing with 70% etha-
nol (ToTALLY RNA kit, Ambion) or by using the RNeasy
kit (Qiagen). All RNA samples were treated with DNase I
(Qiagen) prior to quantitative RT-PCR. Concentrations of
RNAs were determined by reading the absorbance at 260
nm.
Quantitative RT-PCR
Quantitative RT-PCR was performed using the ABI
PRISM™ 7700 Sequence Detection System and TaqMan™
chemistry. Reactions contained 0.3 µM of each primer, 0.1
µM probe, 0.25 U/ml MultiScribe reverse transcriptase,
0.4 U/ml RNase inhibitor, and 1x PCR master mix
(Applied Biosystems). Primers and probes used to quanti-
tate the mRNA level of various genes were as follows:
mouse Ptc-1 (forward primer 5'GCCAATGGCCTAAAC-
CGACT, reverse primer 5'AAACCGGACGACACTTGGAG,
probe 5'6FAM-CCCACTCCTTCGCCTGAGCCG-TAMRA),
mouse HIP (forward primer 5'CCACTGACCTCCGATT-
GCTC, reverse primer 5'TGCAGCAGCACTTGCCAG,
probe 5'6FAM-CGGCTCTGTCGAAACGGCTACTACACC-
TAMRA), mouse vWF (forward primer 5'CCG-
GAAGCGACCCTCAGA, reverse primer 5'CGGTCAATTTT-
GCCAAAGATCT, probe 5'6FAM-
TGGCCTCTACCAGTGAGGTTTTGAAGTACACAC-
TAMRA), mouse CD146 (forward primer 5'GGGCCT-
CAGGCAACTTCA, reverse primer 5'TTGGTGCACACG-
GAAAATCA, probe 5'6FAM-
CTCCTTGTGAATCAAAAACCAGTCCACTTGG-TAMRA),
human HIP (forward primer 5'CCCACACTTCAACAG-
CACCA, reverse primer 5'GCACATCTGCCTGGATCGT,
probe 5'6FAM-CCCCGAAGTGTTTGCTCATGGGCT-
TAMRA), human vWF (forward primer 5'TGAAGTAT-
GCGGGCAGCC, reverse primer 5'GCGGTCGATCTTGCT-
GAAG, probe 5'6FAM-
CCTCCACCAGCGAGGTCTTGAAATACAC-TAMRA).
Mouse and human GAPDH and ribosomal RNA probe
and primer sets were purchased from Applied Biosystems.
RNA quantities were determined from a standard curve of
serially diluted total cellular or tissue RNA run in parallel
with each set of reactions. Standard curves had a slope
between -3.1 and -3.3 and correlation coefficients of 0.98
or greater.
Western blot
Total cell lysates were made by lysing cells in 2% SDS,
10% glycerol, and 0.063 M Tris-HCl (pH 6.8) containing
a cocktail of protease inhibitors (Pierce). Lysates were heat
denatured at 95°C for 10 minutes, passed through a 26G
needle to shear DNA, and centrifuged at 10,000 g for 30
minutes to remove insoluble material. Protein concentra-
tions were determined using the BCA assay (Pierce). Con-
ditioned medium samples were diluted 1:1 in Laemmli
sample buffer (Sigma). 50 µg of cell lysate or 20 µl of con-
ditioned medium/sample buffer was resolved on 4–15%
polyacrylamide gels (BMA) and transferred to nitrocellu-
lose (Invitrogen). Even loading of protein samples was
verified by staining with Ponceau S. After overnight block-
ing with 5% nonfat dry milk, 0.05% Tween-20 in phos-
phate-buffered saline, blots were incubated with
antibodies against Shh (sc-1194, Santa Cruz), Myc tag
(Invitrogen), or HIP (provided by Dr. Pao-Tien Chuang,
UCSF). Antibody-antigen complexes were visualized
using horseradish peroxidase-conjugated secondary anti-
bodies (Jackson ImmunoLabs, Santa Cruz) and SuperSig-
nal West Pico chemiluminescent substrate (Pierce).
Hybridization of RNA probes to cancer array
Linearized templates containing a 716-bp fragment of
human HIP cDNA (bases 521–1236 of human HIP cod-
ing sequence) or a 777-bp fragment of human vWF cDNA
(bases 7301–8077 of human vWF coding sequence) were
radiolabelled with 32P-dUTP by in vitro transcription using
the MAXIscript kit (Ambion). The array was pre-hybrid-
ized in Clontech ExpressHyb solution with 100 µg/ml
boiled, sheared salmon testis DNA (SS-DNA) for 2–12
hours at 68°C with rotation. Pre-hybridization solution
was replaced with fresh hybridization solution with SS-
DNA, plus a total of 1.5–1.7 × 107 cpm of 32P-labelled HIP
or vWF probe. Hybridization of the probe proceeded forBMC Cancer 2004, 4:43 http://www.biomedcentral.com/1471-2407/4/43
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16–18 hours at 68°C, followed by four washes in 2X SSC/
0.5% SDS at 68°C, one wash in 0.2X SSC/0.5% SDS at
68°C, and one wash in 2X SSC at room temperature. The
array was exposed to a phosphor-screen for 24–72 hours
and scanned in a Storm phosphor-imager at a resolution
of 50 µm. After hybridization to the HIP probe, the same
array was stripped by boiling in 0.5% SDS and re-scanned
to verify the absence of residual probe before hybridiza-
tion to the vWF probe. Relative levels of HIP and vWF
expression were determined using ImageQuant software
(Molecular Dynamics).
Statistical analysis
All results are expressed as mean ± standard deviation
unless otherwise noted. Statistical significance of differ-
ences was determined using a two-tailed Student's t-test.
Results
HIP is highly expressed in endothelial cells
Ptc-1 and Smo mRNA are expressed in human aortic
endothelial cells (HAEC) at levels comparable to that of
GAPDH, as determined by comparing the threshold cycle
numbers obtained by quantitative RT-PCR (Q-RT-PCR)
(data not shown). Thus HAEC express components of the
Hh pathway that are known to mediate a response to Hh
ligands. However, when HAEC or human umbilical vein
endothelial cells (HUVEC) were treated with conditioned
medium containing functional Shh, the Hh pathway was
not activated as determined by measuring the levels of
mRNA for Ptc-1 and Gli-1, two genes known to be respon-
sive to Hh signaling (data not shown). Shh mRNA levels
in HAEC and HUVEC were near the limits of detection by
the Q-RT-PCR assay and could therefore be estimated at
less than 10-3 copies per cell based on the typical sensitiv-
ity of this assay. Hedgehog-interacting protein (HIP)
binds Hh proteins with an affinity equal to that of Ptc-1
and can function as an antagonist of Ihh signaling in vivo
[4]. Thus we hypothesized that HIP may be expressed in
EC and function to block Hh signaling. Indeed, we found
that HAEC and HDMEC expressed amounts of HIP mRNA
similar to that of GAPDH, as measured by Q-RT-PCR.
Endothelial cell-predominant expression of HIP was dem-
onstrated by Q-RT-PCR analysis of a variety of human and
mouse primary cell strains and immortalized cell lines
and human cancer cell lines representing different tissues.
When normalized to the level of GAPDH mRNA, the level
of HIP mRNA was 100- to 10,000-fold higher in vascular
endothelial cells than in the other cell types examined
(Figure 1). Expression of HIP protein in HAEC, but not in
ZR75-1 or HT-29, was confirmed by Western blot (Figure
1, inset). The observation that HIP mRNA is expressed at
a high level in human endothelial cells suggests that HIP
may inhibit Hh signaling in these cells and may explain
why these cells are unresponsive to Shh.
HIP inhibits Ptc induction by Shh
Conditioned media from 293 cells co-transfected with
Shh and full-length (membrane-anchored) HIP contained
a reduced amount of Shh and had a reduced ability to
induce differentiation in C3H10T1/2 cells compared to
cells transfected with Shh alone, demonstrating that HIP
can sequester Shh [5]. However, there is no direct evi-
dence that cells in which HIP is overexpressed are less
responsive to Shh. In order to test this directly, 293-EBNA
cells were transfected with a Shh expression plasmid.
Western blot analysis demonstrated the presence of Shh
protein in the conditioned medium from these cells (Fig-
ure 2, inset left). Exposure of TM3 mouse Leydig cells, a
cell line with no detectable endogenous HIP mRNA (Fig-
ure 1), to increasing amounts of conditioned media con-
taining Shh resulted in induction of the Shh pathway, as
measured by a dose-dependent increase in the amount of
endogenous Ptc-1 mRNA (Figure 2). When TM3 cells were
transfected with a plasmid expressing full-length, N-ter-
minally Myc-tagged mouse HIP, the induction of Ptc-1
mRNA by Shh was reduced by 79 percent (p < 0.05; Fig.
2), demonstrating that HIP functions as an inhibitor of
the Shh pathway when expressed in the responding cells.
Expression of HIP in transfected TM3 cells was verified by
Western blot using a Myc antibody (Fig. 2, inset right).
HIP is downregulated in endothelial cells during tube 
formation in vitro
Shh has been shown to induce angiogenesis [7], and HIP
is able to antagonize the Shh pathway (Figure 2). There-
fore, we tested whether HIP expression is downregulated
in EC during tube formation, an essential step in the ang-
iogenic process. Expression of HIP mRNA in HAEC that
had formed tubes on Matrigel as measured by Q-RT-PCR
was 2.9-fold lower (p < 0.05) than in the same cells cul-
tured in standard plastic dishes (Figure 3A). To investigate
whether there was a coordinated downregulation of Hh-
regulated genes during tube formation on Matrigel, the
mRNA level of Ptc-1, a known Hh-responsive gene, was
measured. In contrast to HIP, levels of Ptc-1 mRNA
increased 2.5-fold (p < 0.05) in cells on Matrigel com-
pared to plastic (Figure 3B).
HIP is downregulated in human tumors compared to 
normal tissues
Angiogenesis is a common feature of tumor growth
(reviewed in [16,17]. It is conceivable that HIP is down-
regulated in this process, similar to the reduction we
observed in endothelial cells during tube formation.
Therefore, we measured HIP mRNA levels in a variety of
tumor samples. Tumor and corresponding normal tissue
RNA samples (normal and tumor tissues were from differ-
ent individuals) were obtained from two different com-
mercial sources (Ambion and BioChain), and the
endothelial cell marker vWF was used to normalize HIPBMC Cancer 2004, 4:43 http://www.biomedcentral.com/1471-2407/4/43
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expression to the number of endothelial cells present in
the tumors. In all tissue and tumor RNA samples assayed,
vWF mRNA was detectable. In both pairs of liver tissue
examined, HIP mRNA was expressed in normal tissue but
was undetectable in the tumor (Table 1). One of two kid-
ney tumor-normal pairs showed no difference in normal-
ized HIP expression, while the other showed a 5.9-fold
reduction of normalized HIP in tumor relative to normal
tissue. Of the two breast tissue pairs, one had undetectable
levels of HIP in both normal and tumor tissues (data not
shown), while the other showed a 3.7-fold decrease in
HIP expression in tumor compared to normal. In one
lung tissue pair, vWF levels in normal tissue were over
900-fold lower than in the tumor, such that normaliza-
tion of HIP to vWF resulted in an apparent 30-fold
increase in HIP in tumor compared to normal tissue. In
the other lung tissue pair, normalized HIP was 8.1-fold
lower in tumor than in normal tissue.
To further investigate the frequency of the change in HIP
expression in human tumors, a cancer profiling array
(Clontech) containing cDNA from 154 tumor and corre-
sponding normal tissues from individual patients was
used to compare the expression of HIP in a larger set of
samples. A 32P-labelled HIP probe corresponding to bases
521–1236 of human HIP cDNA was hybridized to the
array, and relative levels of HIP expression were quanti-
tated on a phosphoimager. HIP expression levels were
Comparison of HIP expression in different cell types Figure 1
Comparison of HIP expression in different cell types. Total RNA from each cell type was assayed for HIP and GAPDH 
mRNA levels by Q-RT-PCR. Relative HIP mRNA expression was normalized to GAPDH and plotted on a log scale. Open bars, 
immortalized or cancer cell lines; filled bars, normal cells. TM3, mouse testicular epithelial cell line; ZR75-1, human breast can-
cer cell line; HT-29, human colon cancer cell line; HepG2, human liver cancer cell line; HEK293, human kidney cancer cell line; 
1321N1, human brain cancer cell line; HeLa, human cervical cancer cell line; AMM, activated mouse macrophage; HMEC, nor-
mal human mammary epithelial cells; WI-38, normal human lung fibroblasts; HuSKMC, normal human embryonic skeletal mus-
cle cells; HDMEC, normal human dermal microvascular endothelial cells; HAEC A and HAEC B, normal human aortic 
endothelial cells from two different donors (obtained from Cascade Biologics and Clonetics, respectively).
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normalized to the expression of the endothelial marker
vWF, by re-probing the same array with a fragment of the
human vWF cDNA, as different tumors and normal tis-
sues may contain different degrees of vascularization. In
liver, stomach, colon, and rectum, all or most of the
paired samples showed a reduction of HIP in tumor com-
pared to normal tissue (Table 2). In total, 28 samples had
a decrease in the tumor, while only 3 samples showed a
slight increase (1.3- to 1.7-fold), and 2 samples showed
no change. The lung samples did not show a consistent
patten of HIP mRNA expression. Five had a decrease of
HIP mRNA in the tumor, while four had an increase and
one showed no change. The remaining sets of paired nor-
mal and tumor tissues, including samples from breast,
ovary, vulva, uterus, cervix, prostate, testis, thyroid, skin,
bladder, small intestine, and pancreas, showed no marked
difference in HIP expression between normal and tumor,
or had undetectable HIP expression in both normal and
tumor.
HIP expression is very low or undetectable in xenograft 
tumors
Mouse xenograft tumors resulting from transplantation of
PC3 (human prostate cancer cell line) or A549 (human
lung cancer cell line) cells into nude mice are known to
have high levels of neovascularization as a result of angio-
genesis, which is required for their continued growth
[18,19], so we hypothesized that HIP expression would be
lower in these tumors than in normal tissues that also
contain normal vessels. RNA extracted from PC3 or A549
tumors weighing an average of 350 mg that were excised
39 (PC3) or 9 (A549) days after subcutaneous implanta-
tion, or from liver or skin from non-implanted nude mice,
was assayed for murine HIP, vWF, CD146, and GAPDH
mRNA by Q-RT-PCR. The Q-RT-PCR assay for murine HIP
is species-specific, i.e. does not detect human HIP mRNA
(data not shown). Therefore, any HIP mRNA detected
using this assay must be from host mouse cells present in
the tumor, not from the human tumor cells themselves.
Murine rather than human HIP was assayed because
Expression of HIP in responding cells blocks Ptc-1 induction by Shh Figure 2
Expression of HIP in responding cells blocks Ptc-1 induction by Shh. Untransfected mouse TM3 cells (first three pairs 
of columns) or TM3 cells transfected with empty vector or a vector expressing mouse HIP (last two pairs of columns) were 
exposed to Shh conditioned media at the indicated concentrations (% v/v in normal growth media) for two days, after which 
Ptc and GAPDH mRNA levels were measured by Q-RT-PCR. Ptc-1 mRNA level was then normalized to that of GAPDH. Val-
ues shown for Shh conditioned media treatment (filled bars) are normalized to those obtained with mock conditioned media 
(open bars). Results shown are the mean of three experiments performed in duplicate. Error bars show standard deviation. 
The decrease in normalized Ptc mRNA level for mock- vs. Shh-treated (*) and for HIP- vs. vector-transfected (+) cells was sta-
tistically significant (p < 0.005, two-tailed Student's t-test). Left inset, Western blot showing Shh protein expression in condi-
tioned media from Shh-transfected 293-EBNA cells. Right inset, Western blot showing HIP protein expression in conditioned 
media from HIP-transfected TM3 cells.
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tumors have been shown to incorporate vasculature from
the surrounding vessels [20-22] and there is evidence that
tumors can recruit endothelial and hematopoietic precur-
sor cells [23] to form their own vasculature. RNA from
tumors and normal liver and skin contained measurable
amounts of the murine endothelial cell markers vWF and
CD146, indicating the presence of endothelial cells (Fig-
ure 4). For the PC3 xenograft experiment, the levels of
vWF and CD146 mRNA normalized to GAPDH were actu-
ally higher in the tumors than in the normal liver, consist-
ent with the highly vascularized nature of these tumors. In
contrast, mouse HIP mRNA was abundant in all liver and
skin samples examined but was 16- to 30-fold lower in
A549 tumors and undetectable in any of the PC3 tumor
samples (Figure 4A). These data demonstrate that
although the tumors contained endothelial cells, they
expressed markedly reduced or undetectable amounts of
HIP mRNA.
Discussion
Our demonstration that HIP functions to inhibit Ptc-1
upregulation in mouse testicular epithelial cells (TM3)
exposed to Shh-containing conditioned media is the first
direct evidence to date that Shh signaling is attenuated in
cells that express full-length, membrane-bound HIP. The
decrease in Ptc-1 induction caused by transfection with
HIP is consistent with previous reports indicating that HIP
can bind and reduce the availability of Shh and presuma-
HIP mRNA expression under in vitro angiogenic conditions Figure 3
HIP mRNA expression under in vitro angiogenic conditions. A, HIP or B, Ptc-1 expression in HAEC cultured on plas-
tic (control, filled bar) or on Matrigel (open bar). RNA was harvested from cells 16 hours after seeding on plastic or Matrigel, 
when tubes had fully formed on Matrigel, and assayed for HIP and 18s rRNA, or Ptc-1 and GAPDH mRNA, by Q-RT-PCR. The 
mean data are plotted as relative HIP mRNA normalized to 18s rRNA, or Ptc-1 mRNA normalized to GAPDH mRNA, and are 
the average of three (HIP) or two (Ptc-1) independent experiments performed in triplicate. Error bars show standard devia-
tion. Differences in normalized HIP or Ptc-1 expression were significant for control vs. Matrigel (*p < 0.05, two-tailed Student's 
t-test).
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Table 1: HIP mRNA expression in human normal vs. tumor 
tissues.
HIP/vWF*
Tissue Normal Tumor Tumor/normal
Liver 1 0.107 0 0
Liver 2 2.357 0 0
Kidney 1 0.306 0.051 0.17
Kidney 2 0.272 0.299 1.10
Breast 0.051 0.014 0.27
Lung 1 0.018 0.002 0.11
Lung 2 0.026 0.779 29.97
*Values are HIP mRNA expression normalized to that of vWF.BMC Cancer 2004, 4:43 http://www.biomedcentral.com/1471-2407/4/43
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bly prevent it from signaling through Ptc-1 [4,5]. In
human aortic endothelial cells (HAEC), which express
high levels of HIP, the addition of Shh-containing
conditioned medium did not cause induction of Ptc-1,
even though these cells express the receptor components
Ptc-1 and Smo. In addition, others have shown that
although Shh induces angiogenesis in a mouse model of
hindlimb ischemia, it has no effect on endothelial cell
Table 2: Fold change in HIP for human tumor vs. normal tissues.
Tissue Sex Race Age Tumor additional information HIP tumor/normal*
Liver M C 59 Primary cancer of the liver 0.41
M C 36 Primary cancer of the liver 0.06
M C 58 Primary cancer of the liver 0.03
HIP decreases in 3/3
Stomach M C 63 Adenocarcinoma 0.16
M C 57 Gastric cancer 1.61
M C 47 Gastric cancer 0.24
M C 65 Adenocarcinoma 0.21
M C 61 Adenocarcinoma 0.24
M C 50 Mucinous adenocarcinoma 0.53
F C 72 Adenocarcinoma 0.68
F C 67 Adenocarcinoma 0.37
M C 75 Adenocarcinoma 0.03
F C 68 Adenocarcinoma 0.21
HIP decreases in 9/10
Colon F C 67 Adenocarcinoma 0.25
F C 58 Tubulovillous adenoma 0.23
F C 43 Adenocarcinoma 0.85
F C 69 Adenocarcinoma 1.34
F C 35 Adenocarcinoma 0.41
M C 58 Adenocarcinoma 0.4
M C 63 Adenocarcinoma 0.24
F C 73 Adenocarcinoma 0.16
F C 65 Adenocarcinoma 1.68
F C 65 Adenocarcinoma 0.14
HIP decreases in 8/10
Rectum F A 44 Mucinous adenocarcinoma 0.25
M C 68 Adenocarcinoma 1.1
F C 49 Adenocarcinoma 0.18
F C 59 Adenocarcinoma 0.22
F C 53 Mucinous adenocarcinoma 0.08
F C 70 Adenocarcinoma 1.05
M C 42 Adenocarcinoma 0.79
F C 71 Adenocarcinoma 0.59
F C 59 Adenocarcinoma 0.15
M C 43 Adenocarcinoma 0.56
HIP decreases in 8/10
Lung F C 69 Bronchiolo-alveolar adenocarcinoma 6.45
M C 72 Central cancer of the right lung 0.36
M C 66 Central cancer of the middle lobe of rt lung 0.23
M C 51 Peripheral cancer of the upper lobe of rt lung 0.45
M C 63 Squamous cell carcinoma, keratinizing type 5.49
M C 62 Squamous cell carcinoma, keratinizing type 0.19
M C 67 Squamous cell carcinoma 0.4
M C 71 Squamous cell carcinoma, keratinizing type 0.95
M C 65 Adenocarcinoma 4.9
M A 52 Squamous cell carcinoma 7.08
HIP decreases in 5/10
*HIP tumor/normal value is the vWF-normalized quantity of HIP for the tumor, divided by the vWF-normalized quantity of HIP for the 
corresponding normal tissue.BMC Cancer 2004, 4:43 http://www.biomedcentral.com/1471-2407/4/43
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proliferation or migration in cell culture [7]. Our finding
that vascular EC express abundant amounts of HIP mRNA
may explain the inability of these cells to respond to Shh.
An analysis of various human cell lines and primary cells
indicated that HIP is absent or expressed at low levels in
other cell types, suggesting that in adults HIP is expressed
primarily in EC. These results are supported by gene chip
data analysis of more than 30 normal human tissues
showing that HIP is most highly expressed in blood ves-
sels or in vascular-rich tissues such as liver, lung, brain,
and pancreas (data not shown). These results suggest a
role for HIP in the normal function of blood vessels.
Several lines of evidence support the hypothesis that HIP
expression is decreased in EC participating in angiogen-
esis. Firstly, we describe that HIP is downregulated in
HAEC forming tubes on Matrigel. In contrast, Ptc-1
mRNA levels were increased in EC forming tubes on
Matrigel, suggesting that the decrease in HIP mRNA under
these conditions does not reflect a general downregula-
tion of Hh-responsive genes. Given that transcription of
HIP and Ptc-1 are both activated by Hh signaling, it is
likely that the decrease in HIP expression in EC on
Matrigel is mediated by a pathway independent of Hh sig-
naling. Secondly, we have observed that HIP mRNA levels
are decreased in human tumors and xenograft human
tumors grown in mice, situations in which angiogenesis
occurs. Previous studies have demonstrated a requirement
for Shh in angiogenesis in the ischemic mouse limb and
embryonic yolk sac [8,9]. The pro-angiogenic activity of
exogenously supplied Shh protein has been attributed to
the induction of factors such as VEGF and angiopoietin in
fibroblasts [7]. Our data suggest the possibility that in
situations where HIP expression is downregulated, Hh
may also act directly on endothelial cells.
The Shh pathway has been implicated in several different
types of cancer, where upregulation of signaling, associ-
ated with mutations in Patched or amplification of Gli, is
often the suspected cause of malignancy [11,12,24-26]. In
at least one type of human cancer, basal cell carcinoma
(BCC), HIP upregulation has been demonstrated [27,28],
probably as a result of dysregulation of the Shh signaling
pathway. More recently it has been reported that Hh
pathway activity is activated in a wide variety of digestive
tract tumors by overexpression of the Hh ligand, and is
essential for tumor growth [13]. Aberrant expression of
Shh and activation of Hh signaling was also demonstrated
to occur in pancreatic cancer [14] and small cell lung can-
cer [15]. Hh ligands secreted by tumor cells have the
potential to induce Hh pathway activation in nearby non-
tumor cells, including fibroblasts and endothelial cells.
Our observation that HIP mRNA expression decreases in
several human tumor types relative to normal tissues sug-
gests that modulation of HIP expression may also
promote increased Hh signaling in certain tumors and
contribute to cancer progression. However, since expres-
sion of HIP is known to be induced by activation of the
Hh pathway, an alternative interpretation is that a
reduced level of HIP mRNA in tumors is indicative of
reduced Hh signaling, as suggested by Hu et al. [29]. Our
finding that, in endothelial cells in Matrigel, HIP mRNA
levels decrease while Ptc-1 levels increase demonstrates
that a mechanism other than Hh signaling can modulate
HIP mRNA expression in normal mouse tissues vs. PC3 and  A549 tumors Figure 4
HIP mRNA expression in normal mouse tissues vs. 
PC3 and A549 tumors. 100 ng of RNA extracted from A, 
normal livers or PC3 human prostate xenograft tumors from 
nude mice, or B, normal livers, normal skin, or A549 tumors 
from nude mice, were assayed for vWF, CD146, and HIP 
mRNA expression by Q-RT-PCR. The vWF (white bars), 
CD146 (gray bars), and HIP (black bars) mRNA levels were 
normalized to the GAPDH mRNA level in each RNA sample 
and are presented as the mean with standard deviation (A, N 
= 3 for normal liver, N = 8 for PC3 tumor; B, N = 5 for nor-
mal liver, N = 5 for normal skin, N = 3 for A549 tumor). nd 
= not detectable (no signal from Q-RT-PCR assay after 40 
cycles).
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the expression of these Hh target genes. Thus, the down-
regulation of HIP in tumors may be unrelated to Hh path-
way activity. The precise mechanism of HIP regulation by
the Hh pathway in the context of tumors remains to be
elucidated by future studies. Among the tumor types rep-
resented on the Clontech Cancer Profiling Array, liver and
several areas of the digestive tract (stomach, colon, rec-
tum) exhibited consistent downregulation of HIP in the
tumor relative to normal tissue. Tumors from other tis-
sues, including breast, testis, and kidney, did not show a
significant change in HIP expression from the normal tis-
sue, suggesting that this phenomenon may be restricted to
certain tumor types. Differences in the degree of vascular-
ization of the various tumors may also explain why a
decrease in HIP was not seen in all tumor types.
Xenotransplantation of PC3 or A549 cells into immuno-
compromised mice is a commonly used animal model for
prostate or lung cancer, respectively. Extensive neovascu-
larization occurs in the resulting tumors, and it has been
demonstrated that angiogenesis inhibitors slow their
growth [30,31]. The discovery that vWF-normalized
mouse HIP mRNA levels were markedly decreased in
A549 tumors and undetectable in all of the PC3 tumors
we examined gives further weight to the hypothesis that
decreased HIP expression is associated with tumor
angiogenesis.
Angiogenesis has been well-characterized as a prerequisite
to continued tumor growth and metastasis [16,17,32],
and many approaches have been developed to attempt to
control the progression of cancer by inhibiting angiogen-
esis [32,33]. A more complete analysis of the gene expres-
sion changes in endothelial cells during developmental
and pathological processes should help to identify addi-
tional signaling pathways that are altered and that could
be manipulated to control angiogenesis and disease pro-
gression. The identification of Shh as an angiogenic sign-
aling molecule [7], along with the characterization of HIP
as an inhibitor of Shh that is downregulated in certain
tumors, strongly suggests that inhibition of the Shh path-
way may be of therapeutic use in various cancers that rely
on angiogenesis for their continued growth.
Conclusions
We have shown that HIP is expressed predominantly in
EC but at low or undetectable levels in other cell types,
and that the high expression of HIP in EC may be respon-
sible for their inability to respond to Shh. Expression of
HIP in TM3 cells attenuated their response to Shh, dem-
onstrating that HIP antagonizes Hh signaling when
expressed in the responding cell. The reduction of HIP in
a variety of human tumor samples as well as PC3 and
A549 xenograft tumors, and in EC undergoing tube for-
mation on Matrigel, suggests that modulation of HIP may
play a role in tumor angiogenesis.
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